Clinical Trials Logo

Clinical Trial Summary

This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with MIBC who are ctDNA positive and are at high risk for recurrence following cystectomy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04660344
Study type Interventional
Source Hoffmann-La Roche
Contact Reference Study ID Number: BO42843 https://forpatients.roche.com
Phone 888-662-6728 (U.S. and Canada)
Email global.rochegenentechtrials@roche.com
Status Recruiting
Phase Phase 3
Start date May 3, 2021
Completion date April 1, 2031

See also
  Status Clinical Trial Phase
Recruiting NCT04687254 - Gender-related Characteristics of Bladder Cancer Treatment
Recruiting NCT04099589 - Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma Phase 2
Active, not recruiting NCT03661320 - A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer Phase 3
Active, not recruiting NCT02462239 - Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging N/A
Withdrawn NCT03832673 - Pembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR Study Phase 2
Recruiting NCT06373055 - Prediction of Therapeutic Response to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer Patients Using Spatial Transcriptomics
Recruiting NCT06335667 - mpMRI Compared to Diagnostic TURBT in Patients With Suspected Muscle-Invasive Bladder Cancer N/A
Terminated NCT03234153 - Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin Phase 2
Recruiting NCT05945108 - Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER
Recruiting NCT06362330 - Multi-parametric MRI in Patients of Bladder Cancer
Completed NCT04209114 - A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer Phase 3
Active, not recruiting NCT00808639 - Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma Phase 2